SNDK Sandisk Corporation Common Stock Loading...

From CI earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
13:30
Feb 05 ◎
Brian Avenko President and Chief Operating Officer, The Cigna Group CI Q4 FY25 call
Biosimilar momentum is a major driver. Humira biosimilar penetration is now the vast majority of eligible scripts, with plans for $0 out-of-pocket on Stelara biosimilars. — Confirms the rapid conversion to biosimilars, which will pressure originator brands but provide savings that Cigna can use to offset its own margin pressures.
SNDK
MED

About SNDK Analyst Coverage

Buzzberg tracks SNDK (Sandisk Corporation Common Stock) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 1 total trade idea tracked. Latest voices: Brian Avenko.